Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | ADAM23 |
| Gene Name: | ADAM23 |
| Protein Full Name: | Disintegrin and metalloproteinase domain-containin |
| Alias: | ADA23; ADAM metallopeptidase domain 23; MDC3 |
| Mass (Da): | 91926 |
| Number AA: | 832 |
| UniProt ID: | O75077 |
| Locus ID: | 8745 |
| COSMIC ID: | ADAM23 |
| Gene location on chromosome: | 2q33 |
| Cancer protein type: | TSP |
| Effect of cancer mutation on protein: | UNCLEAR |
| Effect of active protein on cancer: | INHIBITS |
| Number of cancer specimens: | 19719 |
| Percent of cancer specimens with mutations: | 1.05 |
| Gene undergoes hypermethylation: | Gastric, Breast, Brain, Pancreatic, colorectal and Head and Neck cancers |
| Normal role description: | Like many ADAM proteins it contains metalloprotease, disintegrin, cystein-rich, epidermal growth factor-like, transmembrane and cytoplasmatic domains. Unlike the ADAM proteins, its metalloprotease domain is non-functional thus ADAM23 is only involved in cell-cell or cell-matrix adhesion interactions. |